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Abstract
Background: The inactivation of tumor suppressor genes follows Alfred Knudson's 'two-hit'
model: both alleles need to be inactivated by independent mutation events to trigger tumor
formation. However, in a minority of tumor suppressor genes a single hit is sufficient to initiate
tumorigenesis notwithstanding the presence of the wild-type allele, a condition known as
haploinsufficiency. The SMAD4 gene is an intracellular mediator of the TGF-β and BMP signal
transduction pathways and a tumor suppressor involved in pancreatic and colorectal tumorigenesis.
In  Smad4-mutant mouse models, haploinsufficiency characterizes the development of
gastrointestinal polyps with initial retention of the wild-type allele and protein expression within
the nascent tumors and in their direct microenvironment. Similarly, germline SMAD4 mutations are
responsible for a subset of patients affected by juvenile polyposis syndrome, an autosomal dominant
intestinal cancer syndrome. To date, the molecular and cellular consequences of SMAD4
haploinsufficiency on TGF-β and BMP signaling and on genome-wide gene expression have not been
investigated.
Results: Here we show that, similar to previous observations in Smad4-mutant mouse models,
haploinsufficiency characterizes a substantial fraction of the juvenile polyps arising in patients with
germline SMAD4 mutations. Also, mouse embryonic and intestinal cells heterozygous for a targeted
Smad4 null mutation are characterized by a corresponding 50% reduction of the Smad4 protein
levels. Reporter assays revealed that mouse Smad4+/- cells exert intermediate inhibitory effects on
both TGF-β and BMP signaling. Genome-wide expression profiling analysis of Smad4+/- and Smad4-
/- cells pinpointed a subset of dosage-dependent transcriptional target genes encompassing, among
others, members of the TGF-β and Wnt signaling pathways. These SMAD4 dosage-dependent
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transcriptional changes were confirmed and validated in a subset of target genes in intestinal tissues
from juvenile polyposis syndrome patients.
Conclusion: Smad4 haploinsufficiency is sufficient to significantly inhibit both TGF-β and BMP
signal transduction and results in the differential expression of a broad subset of target genes likely
to underlie tumor formation both from the mesenchymal and epithelial compartments. The results
of our study, performed in normal rather than tumor cells where additional (epi-) genetic
alterations may confound the analysis, are relevant for our understanding and elucidation of the
initial steps underlying SMAD4-driven intestinal tumorigenesis.
Background
Haploinsufficiency is defined as the condition where
mutation or loss of a single allele is sufficient to alter the
phenotype of a diploid cell [1]. Haploinsufficiency at a
tumor suppressor locus may overcome the need for
somatic loss or mutation of its wild-type allele, predicted
as the rate-limiting event for tumor development by the
Knudson's 'two-hit' model [2]. To date, experimental evi-
dence for haploinsufficiency in cancer predispositions
comes from the analysis of tumors obtained from mouse
models or hereditary cancer patients carrying hetero-
zygous null mutations at known tumor suppressor genes
[3]. The absence of the second hit in a subset of these
tumors has been attributed to many causes, including
inactivation of the remaining allele by alternative mecha-
nisms such as epigenetic silencing, mutations in non-cod-
ing sequences, or to limited sensitivity of the employed
mutation detection protocol. However, bona fide haploin-
sufficiency has been demonstrated for a subset of tumor
suppressor loci including SMAD4 [4-6], an intracellular
mediator of the TGF-β and BMP signal transduction path-
ways [7,8]. Upon TGF-β or BMP signaling, SMAD4 binds
to the receptor-activated SMADs and translocates to the
nucleus where it modulates the transcription of a broad
spectrum of target genes involved in cell growth inhibi-
tion, apoptosis, differentiation, and matrix production [7-
9]. Somatic SMAD4 gene mutations are found in only a
fraction of advanced sporadic colorectal cancers (CRCs)
[10], whereas germline SMAD4 mutations are responsible
for a subset of patients affected by juvenile polyposis syn-
drome (JPS; Online Mendelian Inheritance in Man
174900) [4], an autosomal dominant intestinal cancer
syndrome. Although the original report showing that
SMAD4 germline mutations are responsible for JPS also
contained preliminary data indicating that loss of hetero-
zygosity (LOH) of the wild-type allele occurred in a
minority of the polyps examined [4], the most convincing
evidence for haploinsufficiency at this locus came from
the analysis of mouse models for juvenile polyposis. We
and others showed that mice carrying targeted Smad4
mutations develop gastrointestinal (GI) polyps with ini-
tial retention of the wild-type Smad4  allele; complete
functional loss only occurs at later stages of tumor pro-
gression within the epithelial compartment [5,6]. Nota-
bly, loss of a single Smad4 allele in the T-cell compartment
and not in the intestinal epithelium resulted in mice char-
acterized by hyperplasia and polyp formation in the GI
tract, similar to the animals with constitutive Smad4
mutations [11]. These data indicate that Smad4 haploin-
sufficiency is likely to play a causative role in GI tumor
formation by exerting a 'landscaping' effect from within
the microenvironment as originally proposed by Kinzler
and Vogelstein [12], and its complete loss of function in
the epithelial cells at later tumor stages accompanies pro-
gression towards malignancy [5,6]. Whether SMAD4
causes polyp formation through haploinsufficiency has
been challenged by two studies showing that the majority
of tumors from JPS patients carrying germline mutations
do show LOH at the wild-type locus [13,14]. These
somatic events occurred both in the epithelial and stromal
components of JPS polyps but not in the infiltrating lym-
phocytes [13].
Here, we have analyzed a cohort of juvenile polyps from
patients with germline SMAD4 mutations for the reten-
tion of protein expression and confirmed that haploinsuf-
ficiency characterizes early stages of polyp formation in a
substantial proportion of the cases. Moreover, we
attempted the elucidation of the molecular basis of Smad4
haploinsufficiency by studying signal transduction and
global gene expression in otherwise normal Smad4+/- cells.
Results
SMAD4 haploinsufficiency underlies human juvenile 
polyposis
Although haploinsufficiency has been thoroughly charac-
terized in mouse models carrying targeted mutations in
the Smad4 gene [5,6], two reports have shown that in the
majority of tumors from JPS patients carrying SMAD4
germline mutations LOH could be detected at the wild-
type allele [13,14]. To clarify this apparent discordance
between mouse and man, and to establish whether
SMAD4 behaves as a classical tumor suppressor gene or if,
analogous to the Smad4  mouse models, haploinsuffi-
ciency underlies early stages of tumor formation in man,
we performed SMAD4 immunohistochemistry (IHC)
analysis of juvenile polyps from six unrelated JPS patients
with known SMAD4 germline mutations (Table 1). Out ofPathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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13 polyps analyzed, three (23%) revealed a homogene-
ously negative staining of the epithelial tumor cells, thus
indicating functional loss of the wild-type SMAD4 allele
(Figure 1g and 1h). In the remaining cases, SMAD4
expression was either patchy with groups of negative
glands scattered among positive ones (n = 6, 46%; Figure
1c to 1f), or showed clear retention of SMAD4 expression
(n = 4, 31%; Figure 1a and 1b). As far as the tumor-asso-
ciated stroma is concerned, different mesenchymal cell
types, for example stromal fibroblasts and infiltrating
lymphocytes, showed in almost all cases SMAD4 nuclear
reactivity amidst a variable number of negative cells (Fig-
ure 1). However, no relationship could be established
between the percentage of SMAD4-positive stromal cells
and the loss/retention of expression in the adjacent epi-
thelial glands. Also, although the total number of tumors
analyzed is admittedly small, no correlation could be
found between polyp size and loss/retention of SMAD4
expression.
Overall, the IHC results confirm that in a substantial pro-
portion of the polyps here analyzed from JPS patients
with SMAD4 germline mutations, tumor onset does not
follow Knudson's two-hit model as SMAD4 expression is
retained in either all or in a considerable proportion of the
epithelial tumor cells. In these cases, as previously shown
in the Smad4+/E6sad mouse model [6], haploinsufficiency is
likely to underlie juvenile polyp onset, whereas later
stages of tumor progression are accompanied by loss of
the wild-type allele.
Smad4 haploinsufficiency results in partial inhibition of 
TGF-β and BMP signaling
In order to study the transcriptional and signal transduc-
tion defects arising from haploinsufficiency at the Smad4
tumor suppressor gene, we employed mouse embryonic
stem (ES) cells where a null mutation, namely a single
nucleotide deletion in the exon 6 splice acceptor site
resulting in an unstable mRNA, is present in the endog-
enous locus [6,15]. The choice of ES cells as a cellular
model to study Smad4  haploinsufficiency was made
mainly based on observations that different components
of the parenchymal and microenvironmental compart-
ments are likely to contribute to polyp initiation and pro-
gression to malignancy [5,6,11], as described above. ES
cells represent the inner cell mass of the pre-implantation
blastocyst and thus precede the differentiation of the three
main germ layers. Moreover, the employment of normal
rather than neoplastic cells allows bypassing of confound-
ers caused by the altered cellular physiology characteristic
of tumor cells and focuses on the primary molecular and
cellular consequences of Smad4 haploinsufficiency. The
Table 1: Results of the immunohistochemical analysis of intestinal polyps from Juvenile Polyposis syndrome patients carrying 
established SMAD4 germline mutations.
SMAD4 Germline Mutation Epithelial SMAD4 expression Stromal SMAD4 expression
Nucleotide [ref.] Amino Acid
JPS case #1
polyp A nt 1042–43, 2 bp del, TTGTTA-TTTA [4] FS 350X -+
polyp B nt 1042–43, 2 bp del, TTGTTA-TTTA [4] FS 350X --
JPS case #2
polyp A nt 424+1, intron 2 TTGg-TTGa  splice defect +/- +
JPS case #3
polyp A nt 1058 TAC-TCC [40] Tyr353Ser +/- +
polyp B nt 1058 TAC-TCC [40] Tyr353Ser ++
polyp C nt 1058 TAC-TCC [40] Tyr353Ser ++
JPS case #4
polyp A nt 533 TCA-TGA [40] Ser178X +/- +
polyp B nt 533 TCA-TGA [40] Ser178X ++
JPS case #5
polyp A nt 687–692, 1 bp ins, TGGGGGGC- 
TGGGGGGGC [4]
FS 235X ++
polyp B nt 687–692, 1 bp ins, TGGGGGGC- 
TGGGGGGGC [4]
FS 235X --
polyp C nt 687–692, 1 bp ins, TGGGGGGC- 
TGGGGGGGC [4]
FS 235X +/- +/-
JPS case #6
polyp A nt 1244–47, 4 bp del, AGACAGAG-AGAG 
[4]
FS 434X +/- +
polyp B nt 1244–47, 4 bp del, AGACAGAG-AGAG 
[4]
FS 434X +/- +
In the last two columns, +, +/-, and - indicate homogeneously positive, patchy, and homogeneously negative nuclear SMAD4 staining, respectively 
(for examples of the various staining patterns, see Figure 1).PathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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alternative use of mouse embryonic fibroblasts (MEFs)
was made impossible by the early in utero lethality charac-
teristic of the Smad4E6sad/E6sad embryos which precludes
MEFs isolation with this genotype [15].
First, we evaluated Smad4 protein expression in wild-type
(Smad4+/+), heterozygous (Smad4+/E6sad), and
homozygous (Smad4E6sad/E6sad) ES cells obtained from pre-
implantation blastocysts of interbred C57Bl6/J Smad4+/
E6sad  mice. To this aim, two independent hetero- and
homozygous ES clones were analyzed by western blot. As
shown in Figure 2 (upper panel), Smad4E6sad/E6sad cells did
not reveal any protein expression thus confirming the null
nature of this mutation, whereas heterozygous ES lines
showed a consistent reduction in protein expression when
compared with wild-type ES cells, indicative of their hap-
loinsufficiency at the protein level. Moreover, western
analysis of intestinal cells from Smad4+/E6sad mice vali-
dated the protein haploinsufficiency in adult tissues (Fig-
ure 2, lower panel).
To determine whether the observed reduction of Smad4
expression in mouse Smad4+/E6sad ES and intestinal cells
impairs TGF-β and BMP signaling, we measured the levels
of the Smads transcriptional complex by a TGF-β reporter
assay system [16]. Due to the insufficient expression levels
of the type II TGF-β receptor (TBRII) in ES cells (data not
shown), TGF-β reporter assay constructs were co-trans-
fected with an expression vector (pCMV5-TBRII) encod-
ing for the TBRII receptor [17]. A dose-response assay was
subsequently performed which indicated that a TGFβ 1
concentration of 50 pmol provides the highest response
in the TBRII-transfected cells (data not shown). As
depicted in Figure 3A, Smad4E6sad/E6sad ES cells demon-
strated a dramatic decrease in TGF-β signaling activity
when compared with the wild-type controls. Notably,
decreased TGF-β activity is already apparent in Smad4+/
E6sad ES clones, characterized by an intermediate yet highly
significant (p < 0.001) level of luciferase activity between
wild-type and homozygous cells. The difference between
Smad4+/+  and  Smad4+/E6sad  ES cells was not significant
when untransfected cells were employed.
Similar results were obtained by analyzing the Smad4-
mutant ES cells for BMP signaling levels by the BRE-luc
reporter assay transfected together with a constitutively
active ActR-I receptor (Alk-2) [18]: while Smad4E6sad/E6sad
ES cells showed a marked decrease in BMP signaling, hap-
loinsufficient cells revealed an intermediate though signif-
icant (p = 0.0024) level between wild-type and Smad4-
deficient ES cells (Figure 3B). Also, rescue of homozygous
Smad4E6sad/E6sad  ES cells by transfection with a human
SMAD4 expression vector [9] fully restored TGF-β signal-
ing (Figure 3C).
Smad4 affects genome-wide gene expression in a dosage-
dependent fashion
In order to further characterize the effects of Smad4 hap-
loinsufficiency on gene transcription, expression profiling
analysis of total RNA samples from wild-type, Smad4+/
E6sad, and Smad4E6sad/E6sad ES cells was performed using the
Affymetrix MOE430 2.0 array. Two independent clones
for each genotype were employed for the analysis. Two
individual lists of differentially expressed genes were gen-
erated by applying a p-value threshold of p < 0.01 and p <
0.05 for the homo- and heterozygous cells, respectively.
Comparison of these two data sets led to the identification
of a signature of 79 differentially expressed genes (31 up-
and 48 down-regulated respectively) common to Smad4
hetero- and homozygous cells, 64 of which (24 up- and
40 down) represent functionally annotated genes (Addi-
tional file 1).
Among the differentially expressed entries, a broad spec-
trum of functional categories is represented: members of
known signal transduction pathways (for example,
Mdm2,  Axin2,  Smad7,  Zak), growth factors (Fgf5,  Fgf8,
Igfbp3,  Lefty2), immunity related genes (Irgm,  Il23a,
Cxcl14), and transcription factors (Nrip1,  Eomes,  Stat3,
Cnot6, T brachyury homolog) (Additional file 1). This is
Immunohistochemical analysis of SMAD4 protein expression in juvenile polyps from patients carrying SMAD4 germline muta- tions Figure 1 (see previous page)
Immunohistochemical analysis of SMAD4 protein expression in juvenile polyps from patients carrying SMAD4 
germline mutations. SMAD4 immunohistochemical analysis of hamartomatous polyps obtained from unrelated Juvenile 
Polyposis syndrome patients with established SMAD4 germline mutations (see Table 1). Images were taken at 10× (a, c, e, g,) 
and 40× (b, d, f, h). Filled (black) arrows indicate cells scored as positive, whereas white arrows point to negatives. a-b. Exam-
ple of a polyp positive for SMAD4 nuclear staining in both the epithelial and stromal compartment (scored as double positive in 
Table 1). c-d. Polyp with heterogeneous SMAD4 expression pattern with patches of positively and negatively staining epithelial 
glands. Most of the stromal cells appear negative with few exceptions. This tumor was scored as +/- (epithelial) and – (stromal) 
in Table 1. e-f. Example of a juvenile polyp with heterogeneous SMAD4 expression in the epithelial compartment but with a 
more pronounced positive staining of the stromal tumor microenvironment. This tumor was scored as +/- (epithelial) and + 
(stromal) in Table 1. g-h. Example of a juvenile polyp characterized by negative SMAD4 staining throughout the epithelial cells. 
In the stromal compartment however, several positively staining cells are present. This tumor was scored as – (epithelial) and 
+ (stromal) in Table 1.PathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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also confirmed by Ingenuity Pathway analysis performed
on the 64 gene signature (Additional file 2). The presence
of Smad4 itself within the list of differentially expressed
genes serves as an internal confirmation of the validity of
our approach. Notably, when the fold changes levels rela-
tive to these 79 genes are plotted in a trend analysis
according to the Smad4  genotypes, the Smad4 dosage-
dependent gradient of transcriptional response becomes
apparent (Figure 4).
In order to validate the observed Smad4 dosage-depend-
ent effect on the transcriptional regulation of a subset of
target genes, we performed quantitative real-time RT-PCR
on laser-capture microdissected (LCM) normal intestinal
cells obtained from two wild-type and three Smad4+/E6sad
animals. From the list of 64 genes differentially expressed
upon Smad4 haploinsufficiency, we selected six known to
be expressed in the GI tract and characterized by at least a
two-fold change in the ES cell expression profiling data
(log2>1). As an internal reference standard, we employed
the Cryzl (crystallin zeta quinone reductase-like 1) gene,
which retains constant expression levels between all ES
and adult intestinal cells (data not shown). Similar to the
ES cells expression profiling results, both up- (Prkar1b and
Tgb1) and down-regulated (Smad7, Irgm, Arts-1 and
Igfbp1) genes showed consistent changes in gene expres-
sion levels in Smad4+/E6sad normal intestinal cells when
compared with intestinal epithelia from wild-type
(Smad4+/+) animals (Figure 5), thus validating the micro-
array expression profiling results.
Discussion
Over the last few years it has become clear that in a subset
of tumor suppressor genes the somatic inactivation or
mutation of the wild-type allele (the second hit) does not
invariably represent the rate-limiting tumor formation
step [1,3,19]. It is generally thought that haploinsuffi-
ciency may affect normal cell function and homeostasis,
possibly in a synergistic manner with other genetic or epi-
genetic somatic hits at unrelated cancer genes. Both JPS
patients and mouse models carrying loss of function
mutations at the SMAD4 tumor suppressor gene represent
illustrative examples of haploinsufficiency in GI tract tum-
origenesis. In partial disagreement with Knudson's two-
Western analysis of Smad4-mutant embryonic stem cell lines Figure 2
Western analysis of Smad4-mutant embryonic stem cell lines. SMAD4 western blot analysis demonstrates haploinsuf-
ficiency in embryonic stem (ES) and adult intestinal cells from Smad4+/E6sad mice. Upper panel: ES cell lysates loaded at two 
different protein amounts; lower panel: normal intestinal tissue lysates from wild-type and Smad4+/E6sad mice.PathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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TGF-β and BMP reporter assay analysis of Smad4-mutant embryonic stem cell lines Figure 3
TGF-β and BMP reporter assay analysis of Smad4-mutant embryonic stem cell lines. TGF-β and BMP reporter 
assay analysis of Smad4-mutant embryonic stem (ES) cell lines. A. TGF-β (CAGA12-MLP-luciferase) and B. BMP (BRE-luci-
ferase) reporter assays were carried out in wild-type (+/+), Smad4+/E6sad(+/-), and Smad4E6sad/E6sad (-/-) ES cell lines. Normalized 
CAGA-luc and BRE-luc levels are indicated for each cell line. For each genotype reporter activities are shown for cells trans-
fected (TBRII+ and ALK2+) and non transfected (TBRII- and ALK2-) with the corresponding receptor-expressing vector. In C. 
the TGF-β reporter assays analysis was carried out after transfection with a SMAD4-expressing vector. Each bar represents the 
average of three independent experiments, and the error bars represent the standard deviation. For the CAGA12-MLP-luci-
ferase assay, three independent ES wild-type clones have been employed. The WT bar represents the average of the luciferase 
activities measured in two independent experiments. p values were calculated by the statistical two samples t-test (two tails).PathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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hit model, somatic loss of the wild-type allele is not a rate-
limiting event in intestinal polyp formation in Smad4-
mutant mouse models [5,6]. Accordingly, as shown in our
study, the majority of polyps from JPS patients carrying
SMAD4  germline mutations retain SMAD4 expression
both in epithelial tumor cells and in their stromal micro-
environment, thus indicating haploinsufficiency. Previ-
ously, Howe et al showed that juvenile polyps from
SMAD4  mutation carriers reveal loss of the wild-type
allele in only 9% (1/11) of their cases [4]. However, the
analysis was done by an exon-specific PCR assay unable to
detect more subtle somatic hits such as point mutations
and epigenetic silencing. Notably, two subsequent and
more thorough reports have shown by LOH, fluorescence
in situ hybridization, and IHC analysis that loss of the
wild-type allele could be detected in the majority of
tumors from JPS patients carrying SMAD4 germline muta-
tions [13,14]. Moreover, SMAD4 loss was observed in
both epithelial and some of the stromal cells, which was
interpreted by the authors as an indication of the clonal
origin of these lesions, and of the fact that SMAD4 repre-
sents a classical 'gatekeeper' tumor suppressor rather than
a 'landscaper' as originally proposed [12,13]. How can the
apparent discordance between the present study and the
reports by Woodford-Richens and colleagues be solved?
From the IHC analysis depicted in Figure 1 it should be
clear that a high degree of heterogeneity in SMAD4 expres-
sion characterizes juvenile polyps both in the epithelial
and mesenchymal compartments. This heterogeneity,
when reduced to more quantitative values as in the case of
PCR-based LOH analysis of whole tumor specimens com-
prehensive of both parenchymal and microenvironmen-
tal cells, may result in loss of accuracy. Also, differences in
interpretation of IHC images may partly underlie this dis-
Trend analysis of Smad4 dosage-dependent transcriptional targets Figure 4
Trend analysis of Smad4 dosage-dependent transcriptional targets. Trend analysis of the 79 genes found to be differ-
entially expressed in both Smad4+/E6sad and Smad4E6sad/E6sad embryonic stem cells. The fold changes are represented as (log2) 
ratio values and plotted as red and green lines for up- and down-regulated genes, respectively.PathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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qPCR validation of the expression profiling results Figure 5
qPCR validation of the expression profiling results. Quantitative PCR analysis of a selection of six genes differentially 
regulated in Smad4+/E6sad cells. Gene expression was quantified in normal intestinal tissues from two wild-type (WT) and three 
Smad4+/E6sad (Smad4) animals and is plotted as ratio over the reference gene (see Materials and Methods). Each bar represents 
the average of three independent experiments.PathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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crepancy. In their IHC analysis of juvenile polyps from
SMAD4-mutant JPS patients [14], Woodford-Richens et al
present an example where, similar to observations in our
study, a heterogeneous staining pattern is observed with
positive epithelial glands amidst negative ones. Last but
not least, both the two-hit and haploinsufficiency models
appear to hold true for SMAD4-driven tumorigenesis, and
this may depend on the molecular nature and pathogenic-
ity of the first hit, namely the germline mutation. As pre-
dicted by the 'just right' model for the APC  tumor
suppressor gene [20,21], the molecular nature of the first
hit at a tumor suppressor locus affects the type of second-
hit mutation at the wild-type allele. It is plausible to think
that while some SMAD4  mutations require functional
inactivation of the wild-type allele to trigger tumor forma-
tion, others can result in juvenile polyp onset without this
otherwise rate-limiting somatic step.
A second important aspect is relative to the role of the
SMAD4 in tumor formation either as an epithelial 'gate-
keeper' or as a 'landscaper', that is, acting from within the
microenvironment to affect epithelial homeostasis [12].
Recently, it was shown that selective loss of Smad4 in the
mouse T-cell compartment results in intestinal adenomas
reminiscent of JPS polyps [11]. Notably, loss of a single
Smad4 allele in T-cells also resulted in hyperplasia and
polyp formation in the intestinal epithelial layer, thus
indicating that Smad4 haploinsufficiency plays a causa-
tive role in GI tumor formation by exerting a 'landscaping'
effect from within the stromal compartment [11]. Con-
versely, our own observation, according to which more
advanced lesions of the Smad4+/E6sad mouse model show
complete loss of Smad4 expression [6], is indicative of an
additional role for the complete loss of Smad4 function in
the epithelial compartment at later tumor progression
stages. Whether the same holds true for SMAD4-driven
juvenile polyp formation in man is still debatable. From
our own IHC analysis (Figure 1), it should be evident that
the SMAD4 expression pattern in the tumor microenvi-
ronment appears rather heterogeneous, with a mixture of
positive and negative stromal fibroblasts and infiltrating
lymphocytes. However, these results are inconclusive in
discriminating between the 'gatekeeper' versus 'land-
scaper' scenarios. In fact, there is little doubt about the
active role played by the tumor microenvironment, espe-
cially in the presence of a TGF-β signaling defect. Previous
reports have shown that loss of function mutations at the
TBRII gene can both trigger epithelial tumorigenesis from
the stromal layer [22] and underlie malignant transforma-
tion when induced in the parenchymal cells of intestinal
adenomas initiated by Apc mutations [23]. Similar obser-
vations were made for the LKB1  gene (also known as
STK11), responsible for Peutz-Jeghers syndrome (PJS;
OMIM 175200), an autosomal dominant predisposition
to hamartomas (polyps of the GI tract with a pronounced
mesenchymal component, very similar to those character-
istic of JPS). Lkb1+/- mice develop intestinal polyps which
often retain the wild type allele [24]. Accordingly, LOH is
not an obligate step in polyps from PJS patients with
germline LKB1 mutations [25]. Notably, monoallelic loss
of murine Lkb1  in the smooth muscle compartment
results in GI polyps indistinguishable from those
observed in mice and in PJS patients with a constitutive
mutation, thus confirming the 'landscaping' role of Lkb1
haploinsufficiency [26]. Further molecular analysis of
these mice revealed that the partial loss of Lkb1 function
results in a TGF-β signaling defect within the stromal com-
partment likely to contribute to polyp formation by gen-
erating a permissive microenvironment for the malignant
transformation of the epithelium [26]. Given the hetero-
geneous composition of the tumor microenvironment
comprising not only stromal fibroblasts but also smooth
muscle cells and various cellular types of immune origin,
it is plausible to think that haploinsufficiency at members
of the TGF-β signaling pathways such as SMAD4 and LKB1
affects cell to cell communication in different tissues, thus
leading to loss of tissue architecture.
In this study, we have shown that Smad4 haploinsuffi-
ciency results in dosage-dependent inhibition of TGF-β
and BMP signaling, thus affecting epithelial cell prolifera-
tion and differentiation both in the stromal and epithelial
compartments and likely to underlie juvenile polyp for-
mation in the intestinal tract. Also, expression profiling of
Smad4 haploinsufficient cells revealed the existence of a
subset of target genes whose expression is specifically reg-
ulated by decreased dosages of this tumor suppressor, pre-
sumably through TGF-β and BMP signaling, as also shown
by the differential expression of two known downstream
targets of the TGF-β pathway, namely Smad7 and Tgfb1.
Smad7 is both an inhibitor of TGF-β signaling and itself a
TGF-β downstream target [27]. Hence, Smad7 down-regu-
lation, as observed in the Smad4+/E6sad ES cells, reflects the
observed TGF-β signaling inhibition. Tgfb1 is an extracel-
lular protein with only poorly characterized functions,
though its significant over-expression, as observed in
Smad4-mutant ES cell lines, has also been reported in spo-
radic CRC [28].
Among the genes shown to be differentially up- or down-
regulated in a Smad4 dosage-dependent fashion, mem-
bers of other signal transduction pathways were also
included (Additional files 1 and 2). Mdm2 up-regulation,
as observed in Smad4+/E6sad cells, may favor tumor trans-
formation by inhibiting p53-mediated transactivation
[29] and by destabilizing retinoblastoma (RB). The gene
encoding for the scaffold protein Axin2 (conductin),
down-regulated in Smad4+/E6sad cells, has been previously
implicated in canonical Wnt signaling and colorectal
pathogenesis [30]. The latter is indicative of cross-talkingPathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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between TGF-β and Wnt signal transduction already in
haploinsufficiency. Down-regulation of the Igfbp3 gene,
encoding for the insulin growth factor binding protein, in
Smad4+/E6sad ES and intestinal cells may also represent a
relevant early step in tumor formation. Igfbp3 has been
described as tumor suppressor gene [31], due to its role in
the regulation of cell proliferation and apoptosis, and its
differential methylation in a substantial fraction of CRC
cases [32].
Overall, Smad4 haploinsufficiency affects both TGF-β and
BMP signaling together with a broad spectrum of tran-
scriptional targets and cellular functions. Future studies
will reveal which of these target genes are preferentially
affected in a specific cellular compartment, and the para-
crine or cell autonomous effect that they exert on epithe-
lial tumorigenesis.
Conclusion
In this study we have shown that haploinsufficiency at the
SMAD4 tumor suppressor locus underlies polyp forma-
tion in a proportion of GI tumors from JPS patients, as
previously shown in Smad4-mutant mouse models. More-
over, SMAD4 haploinsufficiency affects both the TGF-β
and BMP signal transduction pathways together with a
broad spectrum of transcriptional targets and cellular
functions. These results contribute to our understanding
of the cellular and molecular mechanisms underlying
intestinal tumorigenesis due to TGF-β (and BMP) signal-
ing defects not only in the parenchymal cells but also
from within the stromal microenvironment. This is of
fundamental but also of clinical relevance as these dosage-
specific transcriptional targets may offer novel opportuni-
ties in the development of tailor-made therapeutic strate-
gies.
Methods
Generation of Smad4-mutant ES cell lines
Smad4+/E6sad mice, available on the inbred C57Bl/6J back-
ground, were inter-bred and the resulting blastocysts har-
vested at 3.5 dpc. Flushed pre-implantation blastocysts
were then individually cultured on 96-well dishes coated
with MEFs as previously described [33].
All mouse experiments were performed upon approval of
the local animal experiment committee (DEC permis-
sions nr. EUR 596, 600, 623 and 730) and according to
internationally recognized guidelines (as described by the
Code of Practice Dierproeven in het Kankeronderzoek).
Smad4 western analysis
Equal amounts (40 μg) of protein lysates were separated
on 12% SDS polyacrylamide gels, and further subjected to
immunoblotting according to standard procedures. Sev-
eral studies have validated the specificity and sensitivity of
the B-8; sc-7966 monoclonal antibody against SMAD4
(Santa Cruz Biotechnology) to detect alterations of pro-
tein expression in both mouse and human specimens. The
B-8; sc-7966 primary antibody was employed for western
analysis at a 1:100 dilution. Peroxidase-conjugated sec-
ondary antibodies (Jackson Immunoresearch) were visu-
alized with an enhanced chemiluminescence system.
Reporter assay analysis
ES cells grown on tissue culture dishes coated by mitoti-
cally inactivated primary MEFs were transfected by Lipo-
fectamine 2000 (Life Technologies) with 250 ng of the
reporter plasmid ((CAGA)12-MLP-luciferase for the TGF-
β signaling or BRE-luciferase for the BMP signaling), 100
ng of receptor-expressing vector (TGFBRII or, for BMP sig-
naling, a constitutively active form of ALK2) [17,18] (all
kindly provided by Professor P ten Dijke), and 5 ng of a
Renilla reniformis luciferase-expressing vector. For the res-
cue experiments, 100 ng of the Smad4-pCMV5 expression
vector [9] were transfected together with (CAGA) 12-MLP-
luciferase and TGFBRII. After 24 hours, ES cells transfected
with the (CAGA)12-MLP-luciferase were stimulated with
recombinant human TGF-β (50 pmol) for 1 hour before
measuring luciferase activity with the luminometer Fluor-
oskan Ascent CF (Labsystems) using the Dual Luciferase
Reporter Assay system (Promega). Luciferase activities
were calculated as a ratio between the specific luciferase-
reporter construct and the Renilla luciferase levels, for a
total of three different experiments, each carried out in
triplicate. For the CAGA12-MLP-luciferase assay, three
independent ES wild-type clones were used and the aver-
age of their luciferase activities measured in two inde-
pendent experiments.
Immunohistochemical analysis
Formalin-fixed, paraffin-embedded intestinal polyps were
prepared as 4 μm sections and immunostained with the
mouse Smad4 B-8; sc-7966 monoclonal antibody
directed against Smad4 (Santa Cruz Biotechnology Inc,
dilution 1:100). After antigen retrieval treatment (10 min
boiling in Tris-EDTA pH 8.0), endogenous peroxidase was
inactivated with 1% H2O2/PBS. A 30 min pre-incubation
step in 5% non-fat dry milk in PBS was followed by incu-
bation with the Smad4 antibody overnight at 4°C in pre-
incubation buffer. Sections were then stained with the
Envision HRP-ChemMate kit (DAKO). Smad4 IHC stain-
ing was evaluated after brief hematoxylin counterstaining
of the slides.
Expression profiling analysis
Total RNA was labeled using the GeneChip One-Cycle
Target Labeling and Control Reagents kit, and hybridized
to MOE430 2.0 Affymetrix oligonucleotide arrays, accord-
ing to the manufacturers' instructions. Raw signal intensi-
ties were extracted and summarized from cel-files,PathoGenetics 2008, 1:2 http://www.pathogenetics.com/content/1/1/2
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followed by normalization using the robust multi-array
average expression measure implemented in the Biocon-
ductor package affylmGUI [34]. No filtering was applied
to the data. A Bayesian linear regression model was used
to detect differentially expressed genes implemented in
the Bioconductor package limma [35,36]. All Bioconduc-
tor packages were used with R statistical Computing Soft-
ware v2.2.1 [37].
Quantitative real-time RT-PCR analysis
LCM of intestinal tissues (approx. 6000 cells) was per-
formed as previously described [38]. PCR analysis was car-
ried out in triplicate in 25 μl volumes using 1 μl of cDNA
and SYBR® Green Dye (Applied Biosystems) on the MyiQ
Single-Color Real-Time PCR Detection System (Bio-Rad).
Primers sequences are listed below. Standard curves for
the target genes and the reference Cryzl1 gene were gener-
ated and the normalization and ratio were calculated as
described [39], (see Table 2).
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